NAMS Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 days ago - By: Zacks Investment Research - Mentions: SPRY

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates

5 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

21 days ago - By: Benzinga

Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)

3 months ago - By: Benzinga

Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts

5 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

6 days ago - By: Zacks Investment Research - Mentions: MDGL

Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates

11 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

12 days ago - By: Zacks Investment Research - Mentions: CORT

NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?

3 months ago - By: The Motley Fool

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

a month ago - By: CARISTO DIAGNOSTICS

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

2 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

2 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

2 months ago - By: Menarini Industrie Farmaceutiche Riunite

Evropská agentura pro léčivé přípravky (EMA) přijala od skupiny Menarini Group žádost o registraci přípravků Obicetrapib a Obicetrapib/Ezetimib pro léčbu dospělých pacientů s primární hypercholesterolemií (heterozygotní familiární a nefamiliární) nebo

2 months ago - By: Menarini Industrie Farmaceutiche Riunite

Заявки на получение регистрационного удостоверения обицетрапиба и обицетрапиба/эзетимиба от Menarini Group, принятые для рассмотрения Европейским агентством по лекарственным средствам (EMA) для лечения взрослых с первичной гиперхолестеринемией

2 months ago - By: Menarini Industrie Farmaceutiche Riunite

Wnioski o pozwolenie na dopuszczenie do obrotu leków Obicetrapib i Obicetrapib/Ezetimibe firmy Menarini Group zostały przyjęte do rozpatrzenia przez Europejską Agencję Leków (EMA) w zakresie leczenia dorosłych z pierwotną hipercholesterolemią

2 months ago - By: Menarini Industrie Farmaceutiche Riunite

Die Zulassungsanträge der Menarini Group für Obicetrapib und Obicetrapib/Ezetimibe zur Behandlung von Erwachsenen mit primärer Hypercholesterinämie (heterozygote familiäre und nicht-familiäre Form) oder gemischter Dyslipidämie wurden von der Europäischen

2 months ago - By: Menarini Industrie Farmaceutiche Riunite

Les demandes d'autorisation de mise sur le marché de l'obicetrapib et de l'obicetrapib/ézétimibe de Menarini Group ont été acceptées pour examen par l'Agence européenne des médicaments (EMA) pour le traitement des adultes atteints d'hypercholestérolémie

2 months ago - By: Menarini Industrie Farmaceutiche Riunite

Aceptadas las solicitudes de autorización de comercialización de obicetrapib y obicetrapib/ezetimiba

2 months ago - By: Menarini Industrie Farmaceutiche Riunite

Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial)

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

3 months ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions und NewAmsterdam Pharma investieren in einen spezialisierten Produktionsbereich, um die Herstellungskapazitäten fester oraler Darreichungsformen am Piramal-Standort in Sellersville, Pennsylvania, zu erweitern

3 months ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions et NewAmsterdam Pharma investissent dans une unité dédiée pour améliorer les capacités de production de dosages solides oraux sur le site de Piramal à Sellersville, en Pennsylvanie.

3 months ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

3 months ago - By: Zacks Investment Research - Mentions: ASRT

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

4 months ago - By: NewAmsterdam Pharma N.V.

NEWAMSTERDAM PHARMA CO NV (NAMS) Stock News

NAMS Latest News, Press Relases and Analysis

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)

Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Evropská agentura pro léčivé přípravky (EMA) přijala od skupiny Menarini Group žádost o registraci přípravků Obicetrapib a Obicetrapib/Ezetimib pro léčbu dospělých pacientů s primární hypercholesterolemií (heterozygotní familiární a nefamiliární) nebo

Wnioski o pozwolenie na dopuszczenie do obrotu leków Obicetrapib i Obicetrapib/Ezetimibe firmy Menarini Group zostały przyjęte do rozpatrzenia przez Europejską Agencję Leków (EMA) w zakresie leczenia dorosłych z pierwotną hipercholesterolemią

Die Zulassungsanträge der Menarini Group für Obicetrapib und Obicetrapib/Ezetimibe zur Behandlung von Erwachsenen mit primärer Hypercholesterinämie (heterozygote familiäre und nicht-familiäre Form) oder gemischter Dyslipidämie wurden von der Europäischen

Les demandes d'autorisation de mise sur le marché de l'obicetrapib et de l'obicetrapib/ézétimibe de Menarini Group ont été acceptées pour examen par l'Agence européenne des médicaments (EMA) pour le traitement des adultes atteints d'hypercholestérolémie

Aceptadas las solicitudes de autorización de comercialización de obicetrapib y obicetrapib/ezetimiba

Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial)

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Piramal Pharma Solutions und NewAmsterdam Pharma investieren in einen spezialisierten Produktionsbereich, um die Herstellungskapazitäten fester oraler Darreichungsformen am Piramal-Standort in Sellersville, Pennsylvania, zu erweitern

Piramal Pharma Solutions et NewAmsterdam Pharma investissent dans une unité dédiée pour améliorer les capacités de production de dosages solides oraux sur le site de Piramal à Sellersville, en Pennsylvanie.

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025